Role of Bromodomain and Extraterminal (BET) Proteins in Prostate Cancer.

Adel MandlMark C MarkowskiMichael A CarducciEmmanuel S Antonarakis

Published in: Expert opinion on investigational drugs (2023)

The therapeutic potential of BET inhibitors for prostate cancer has been demonstrated in preclinical studies. However, further research is needed to identify biomarkers that can predict sensitivity to BET inhibitors and to develop novel, highly selective inhibitors to reduce toxicities. Finally, BET inhibitors are likely to hold the most clinical potential in combination with other agents.

Keyphrases

prostate cancer
radical prostatectomy
stem cells
bone marrow
case control